Use of Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry to Demonstrate Decreased Serum Statin Levels after Extracorporeal LDL-Cholesterol Elimination
Table 1
Atorvastatin and its metabolites in serum before and after the EE procedure.
Procedure
Compound
Number of samples
p (Wilcoxon nonparametric -test)
Before procedure
After procedure
Average (nmol/L)
Standard deviation
Median (nmol/l) (range)
Average (nmol/L)
Standard deviation
Median (nmol/l) (range)
LDL-apheresis
AT S
16
8.83
5.41
6.86 (3.77–23.90)
3.46
1.76
3.64 (0.01–7.11)
0.000060
p-OH-AT S
16
1.78
1.73
1.49 (0.00–7.59)
0.73
0.43
0.64 (0.00–1.53)
0.007436
o-OH-AT S
13*
4.74
1.99
4.87 (2.18–7.58)
2.63
0.98
2.97 (1.19–4.18)
0.012861
ATL S
16
4.74
2.27
4.34 (2.33–8.82)
1.95
1.49
1.68 (0.33–2.33)
0.000369
Haemorheopheresis
AT S
6
37.02
19.23
40.41 (6.46–59.20)
18.94
14.75
16.58 (1.93–44.26)
0.0092
p-OH-AT S
6
2.89
3.12
1.63 (0.78–8.79)
1.63
1.54
0.80 (0.56–4.30)
0.126
o-OH-AT S
6
19.98
9.50
23.71 (3.58–28.74)
11.19
6.32
12.35 (1.31–19.31)
0.0205
ATL S
6
16.99
9.37
14.98 (2.66–27.85)
9.92
7.27
10.71 (1.02–20.30)
0.0475
Both procedure (LDL-apheresis +haemorhepheresis)
AT S
22
15.84
14.95
8.48 (3.77–49.73)
8.36
12.88
4.25 (0.01–59.20)
0.001150
p-OH-AT S
22
2.04
2.15
1.49 (0.00–8.79)
1.02
1.04
0.69 (0.00–4.30)
0.009816
o-OH-AT S
19
9.18
8.58
5.43 (2.18–28.74)
5.70
6.20
3.15 (1.19–21.97)
0.034282
ATL S
22
8.09
7.46
4.95 (2.33–27.85)
4.12
5.23
1.95 (0.33–20.30)
0.002190
hree other samples were obtained. However, it was technically impossible to measure the samples, as they blocked the extraction SPE supports. p-OH-AT: p-hydroxyatorvastatin. o-OH-AT: o-hydroxyatorvastatin. AT: atorvastatin. S: serum. ATL: atorvastatin lactone.
